Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 9Thoracic 4Genitourinary 4Head & Neck 3Dermatologic 3Gynecologic 2Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 29Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Esophageal Squamous Cell Carcinoma 10Rectal Neoplasms 7Pancreatic Neoplasms 7Biliary Tract Neoplasms 7Head and Neck Neoplasms 5Colonic Neoplasms 5Cholangiocarcinoma 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Ovarian Neoplasms 3Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Anus Neoplasms 3Turcot syndrome 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pathologic Complete Response 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Digestive System Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 39Nivolumab 15Gemcitabine 8spartalizumab 7atezolizumab 7Carboplatin 7Cyclophosphamide 6130-nm albumin-bound paclitaxel 6durvalumab 5Cisplatin 5Bevacizumab 5fludarabine 4budigalimab 4Paclitaxel 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cetuximab 4Albumin-Bound Paclitaxel 4tislelizumab 3lenvatinib 3cemiplimab 3avelumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Irinotecan 3HMPL-013 3Fulvestrant 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Immune Checkpoint Inhibitors × Gastrointestinal × Clear all
NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Maastricht University Medical Center

Phase 1/2 Recruiting
126 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡